SCHEMBL9756822

SCHEMBL9756822

COC(=O)CCCNc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.60
ALDH1A1 P00352 5/20 0.55
MAPT P10636 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.50
TSHR P16473 2/20 0.48
TOP2A P11388 1/20 0.47
POLB P06746 1/20 0.46
CA12 O43570 2/20 0.46
CA9 Q16790 2/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
CA7 P43166 1/20 0.45
CA14 Q9ULX7 1/20 0.45
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1472555 0.93 LMNA (0.66) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL505867 0.89 LMNA (0.55) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL9891436 0.87 TOP2A (0.49) LMNAALDH1A1MAPTSMN1; SMN2TOP2A
SCHEMBL5009825 0.85 TOP2A (0.64) ALDH1A1MAPTSMN1; SMN2TOP2AKDM4E
SCHEMBL9891452 0.83 ALDH1A1 (0.48) LMNAALDH1A1MAPTTOP2APOLB
SCHEMBL3669586 0.83 MAPT (0.51) LMNAALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL4828253 0.83 ALDH1A1 (0.47) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL27471036 0.83 ALDH1A1 (0.52) LMNAALDH1A1MAPTTOP2AHDAC3
SCHEMBL11136638 0.83 LTA4H (0.46) LMNAALDH1A1MAPTSMN1; SMN2TSHR
SCHEMBL11317810 0.83 MAPT (0.61) LMNAALDH1A1MAPTSMN1; SMN2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-07-21 US disclosed
WO-2020240524-A2 METHODS OF TREATMENT OF KIDNEY INJURY ASSOCIATED WITH INFECTION OR TRAUMA UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-12-03 WO disclosed
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF T 2020-07-02 US disclosed
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF T 2020-07-02 US disclosed
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-04-21 US disclosed
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-04-21 US disclosed
US-10160705-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2018-12-25 US disclosed
US-20180312455-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2018-11-01 US disclosed
US-5041518-A Process for the production of polyhydantoins containing amide groups and/or imide groups BAYER AKTIENGESELLSCHAFT (DE) 1991-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160705-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury HDAC1, HDAC9, HDAC11 LMNA 1928/4885ALDH1A1 351/4885MAPT 4107/4885
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma MMP8, PLAU, KLKB1 LMNA 2370/4885ALDH1A1 2405/4885MAPT 3860/4885
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury HDAC1, HDAC9, HDAC11 LMNA 1928/4885ALDH1A1 351/4885MAPT 4107/4885
US-20180312455-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 LMNA 1928/4885ALDH1A1 351/4885MAPT 4107/4885
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 LMNA 1928/4885ALDH1A1 351/4885MAPT 4107/4885
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma HDAC1, HDAC2, HDAC4 LMNA 2466/4885ALDH1A1 1054/4885MAPT 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.